Andrew Beros, MD
Otolaryngology · San Diego, CANPI 1104889054
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $94 of the $118 with a category attached, or 79.7%. 6 manufacturers reported payments, led by AMAG Pharmaceuticals, Inc. at 20.3% of the total. That places this record below the midpoint for otolaryngology clinicians in CA, where the typical reported total is $903.
Across 6 payments — averaging $19.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AMAG Pharmaceuticals, Inc.$24
- Bristol Myers Squibb$23
- Exact Sciences$21
- Integra Lifesciences Corporation$19
- Merck$17
- AstraZeneca$15
Across 6 payments — averaging $114,681 each. An ownership or investment interest held by the physician or an immediate family member.
- Calyxo, Inc.$688K
What the payments were for
- Food & beverage$9480%
- Education$2420%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AMAG Pharmaceuticals, Inc. | 1 | $24 |
| Bristol Myers Squibb | 1 | $23 |
| Exact Sciences | 1 | $21 |
| Integra Lifesciences Corporation | 1 | $19 |
| Merck | 1 | $17 |
| AstraZeneca | 1 | $15 |
How this compares
$118 in reported general payments places this provider in the 20th percentile of 1,021 otolaryngology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mometasone Furoate | 92 | $7,804 |
| Ipratropium Bromide | 60 | $2,228 |
| Fluticasone Propionate | 125 | $1,727 |
| Fluocinolone Acetonide Oil | 14 | $607 |
| Famotidine | 35 | $468 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 33 | $217 |
| Doxycycline Monohydrate | 22 | $178 |
| Omeprazole | 16 | $144 |
| Calcitriol | 17 | $67 |
| Cephalexin | 16 | $56 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in San Diego
- Brian WeeksSan Diego$924K
- Adam DecondeSan Diego$32K
- Theresa GuoSan Diego$24K
- Charles TesarSan Diego$21K
- Charles CoffeySan Diego$20K
- Erik ViirreSan Diego$17K
- Jo-Lawrence BigcasSan Diego$15K
- Randall OwRoseville$613K
- Amir MoradiVista$389K
- Keith BlackwellLos Angeles$349K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.